Sonnet Biotherapeutics Stock Buy Or Sell
We're not expecting sonnet biotherapeutics to pay a dividend over the next 12 months. Get the stock price and latest news for sonn and start trading today with zero commissions.
Is it a better buy than others?
Sonnet biotherapeutics stock buy or sell. And a bulleted list of reasons to buy or sell the stock. Sonnet biotherapeutics is selling for 0.62 as of the 21st of november 2021. Marketbeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
Kenney bought 15,000 shares of sonnet biotherapeutics stock. For sonnet biotherapeutics holdings, inc. The average sonnet biotherapeutics holdings stock price prediction forecasts a potential downside of n/a from the current sonn share price of $0.61.
After each calculation the program assigns a buy. The stock's open price was 0.63. You'll find the sonnet biotherapeutics holdings share forecasts, stock quote and buy / sell signals below.
0 analyst(s) have tagged sonnet biotherapeutics holdings inc. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. So if you had owned 26 shares the day before before the split, the next day you'd have owned 1.
The stock has a consensus analyst rating of buy. a buy rating indicates that analysts believe sonn will outperform the market and that investors should add to their positions of sonnet biotherapeutics. The stock was acquired at an average cost of $1.54 per share, with a total value of $23,100.00. Given the current horizontal trend, you can expect sonnet biotherapeutics holdings inc.
Sonnet biotherapeutics (sonn) quote overview » zacks research » sonnet biotherapeutics (sonn) style scores. What analysts on recommend for this stock, on a scale from 1 (buy) to 5 (sell). 1 wall street equities research analysts have issued buy, hold, and sell ratings for sonnet biotherapeutics in the last twelve months.
The consensus among wall street equities research analysts is that investors should buy sonnet biotherapeutics stock. Looking to buy sonnet biotherapeutics stock? Sonnet biotherapeutics holdings's share price could stay at $6.50 by sep 15, 2022.
A look at the daily price movement shows that the last close reads $0.66, with intraday deals fluctuated between $0.61 and $0.6399. (sonn), analysts’ consensus is at an average recommendation of buy while assigning it a mean rating of 2. Wall street stock market & finance report, prediction for the future:
When looking into those indicators for sonnet biotherapeutics holdings inc. The stock was acquired at an average cost of $1.55 per share, with a total value of $49,600.00. According to present data sonnet biotherapeutics holdings's sonn shares and potentially its market environment have been in bearish cycle last 12 months (if exists).
The stock is at the lower part of a wide and horizontal trend in the short term, and normally this may pose a good buying opportunity, though a breakdown through the bottom trend line at $0.57 will give a strong sell signal and a trend shift may be expected. Pankaj mohan has not been actively trading shares of sonnet biotherapeutics during the past quarter. Which sonnet biotherapeutics insiders have been buying company stock?
Sonnet biotherapeutics's shares were split on a 1:26 basis on 1 april 2020. Since the stock market crash in march caused by coronavirus, sonnet biotherapeutics's stock price has had significant negative movement. Have sonnet biotherapeutics's shares ever split?
Analysts have rated the stock buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares. What analysts think sonn will be worth. Albert d dyrness ($9,130.11), pankaj mohan ($49,600.00), and richard t.
Most recently, on wednesday, june 9th, pankaj mohan bought 32,000 shares of sonnet biotherapeutics stock. There are currently 1 buy rating for the stock. On average, wall street analysts predict that.
Out of them, 0 rate it a hold, while 1 recommend buy, whereas 0 assign an overweight rating. The following insiders have purchased sonnet biotherapeutics stock in the last 24 months: Get the latest sonnet biotherapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including sonnet stock investment advice, charts, stats and more.
View the latest ratings for sonn. Sonnet biotherapeutics currently has 1 buy rating from wall street analysts. Splitting up the data highlights that, out of 1 analysts covering the stock, none rated the stock as a sell while none recommended an overweight rating for the stock.
Kenney has not been actively trading shares of sonnet biotherapeutics in the last ninety days. Most recently, on wednesday, june 9th, richard t. (sonn) as underweight, while 0 advise sell.
Sonn | complete sonnet biotherapeutics holdings inc.
Post a Comment for "Sonnet Biotherapeutics Stock Buy Or Sell"